Clinical considerations of antidepressant prescribing for older patients

New Zealand Medical Journal

Volumn 118, Issue 1222, 2005, Pages

  Kairuz, Therése ^a   Zolezzi, Monica ^a   Fernando III, Antonio ^b  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

AGED; ANOREXIA; ANXIETY; ANXIETY DISORDER; BODY WEIGHT DISORDER; CARDIOTOXICITY; CLOSED ANGLE GLAUCOMA; COMA; COMORBIDITY; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; DELIRIUM; DENTAL CARIES; DENTURE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DYSPHAGIA; EJACULATION DISORDER; FATIGUE; FOOD DRUG INTERACTION; FRACTURE; GERIATRIC CARE; GERIATRIC PATIENT; HUMAN; HYPERTENSIVE CRISIS; HYPONATREMIA; INJURY; INSOMNIA; LETHARGY; LIBIDO DISORDER; MEDICAL LITERATURE; MICTURITION DISORDER; MYDRIASIS; NAUSEA; NEW ZEALAND; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PREVALENCE; QT PROLONGATION; RESTLESS LEGS SYNDROME; RESTLESSNESS; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SOMATIZATION; SYMPTOMATOLOGY; TACHYCARDIA; UPPER GASTROINTESTINAL BLEEDING; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; CLINICAL PRACTICE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; GERIATRICS; METHODOLOGY; TREATMENT OUTCOME;

AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GERIATRICS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 27244460352     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. World Health Organization. Prevention of mental disorders: effective interventions and policy options: Summary report. A report of the World Health Organization Department of Mental Health and Substance Abuse in collaboration with the Prevention Research Centre of the Universities of Nijmegen and Maastricht. Geneva, Switzerland; 2004. Available online. URL: http://www.who.int/mental_health/evidence/en/ prevention_of_mental_disorders_sr.pdf Accessed September 2005.
2. Roberts E, Norris P. Growth and change in the prescribing of anti-depressants in New Zealand: 1993-1997. N Z Med J. 2001;9:25-7.
3. PHARMAC (Pharmaceutical Management Agency). FAQ's and Figures. Wellington: PHARMAC; 2005. Available online. URL: http://www.pharmac.govt.nz/latest_stats.asp Accessed September 2005.
4. Teresi J, Abrams R, Holmes D, et al. Prevalence of depression and depression recognition in nursing homes. Soc Psychiatry Psychiatr Epidemiol. 2001;36:613-20.
5. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry. 2004;38:389-407. Review.
6. Ministry of Health. Health and independence report: director-general's annual report on the state of public health. Wellington: Ministry of Health; 2003.
7. Iliffe S, Haines A, Gallivan S et al. Assessment of elderly people in general practice. 1. Social circumstances and mental state. Br J Gen Pract. 1991;41:9-12.
8. Anon. Deciphering depression in seniors. D.U.E. Quarterly. The Alberta Medical Association and the Alberta Pharmaceutical Association. Edmonton, Canada. October 1995; Issue 8.
9. Anon. Alcohol misuse among the elderly - a hidden problem? Southampton, UK: University of Southampton; 1997. Available online. URL: http://www.soton.ac.uk/~pubaffrs/1997/97127.htm Accessed September 2005.
10. Montano CB. Recognition and treatment of depression in a primary care setting. J Clin Psychiatry. 1994;55(Suppl):18-34 and discussion 35-7.
11. Stewart JT. Why don't physicians consider depression in the elderly? Age-related bias, atypical symptoms, and ineffective screening approaches may be at play. Postgrad Med. 2004;115:57-9.
12. Raj A. Depression in the elderly. Tailoring medical therapy to their special needs. Postgrad Med. 2004;115:26-8, 37-42. Review.
13. Pillans PI, Coulter DM. Fluoxetine and hyponatraemia - a potential hazard in the elderly. N Z Med J. 1994;107:85-6. Review.
14. Kelly RE, Robinson H, Beringer TR. Hyponatremia in an older patient. J Am Geriatr Soc. 1999;47:1037-8.
15. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ. 1996;155:519-27. Review. Erratum in: Can Med Assoc J 1996 Oct 15;155(8):1043.
16. Strachan J, Shepherd J. Hyponatraemia associated with the use of selective serotonin reuptake inhibitors. Aust N Z J Psychiatry. 1998;32:295-8.
17. Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol. 1999;47:211-7.
18. Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry. 2001;16:484-93. Review.
19. Fonzo-Christe C, Vogt N. Abstract [Susceptibility of the elderly patient to hyponatremia induced by selective serotonin reuptake inhibitors]. Therapie. 2000;55:597-604. Review [in French].
20. Valuck R. Selective Serotonin Reuptake Inhibitors: A Class Review. P&T 2004;29: 234-43.
21. Anon. Selective serotonin reuptake inhibitors and upper gastrointestinal bleeding. The Australian Journal of Pharmacy. 2000;81:1111.
22. Effective and safer anti-depressant use. Drug Use in the Elderly. D U E Quarterly. 2001;Issue 30.
23. Amrein R, Stabl M, Henauer S, et al. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview. Can J Psychiatry. 1997;42:1043-50.
24. Russell JM, Koran LM, Rush J, Hirschfield RMA, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. In PharmacoEconomics & Outcomes News. 2001;305:10.
25. South African Medicines Formulary. Editor CJ Gibbon. 5th ed. Cape Town: South African Medical Association Health and Publishing Group; 2002.
26. Cadieux RJ. Antidepressant drug interactions in the elderly. Understanding the P-450 system is half the battle in reducing risks. Postgrad Med. 1999;106:231-2, 237-40, 245-9.
27. Celexa (citalopram) [package insert]. St Louis: Forest Pharmaceuticals; 1998.
28. Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother. 2000;34:871-4.
29. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl. 2001;42:S4-8. Review.
30. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 18):4-11. Review.
31. Schweitzer I, Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf. 1998;19:455-64. Review.
32. Ganzini L, Walsh JR, Millar SB. Drug-induced depression in the aged. What can be done? Drugs Aging. 1993;3:147-58. Review.
33. Mandos LA. Current issues in the diagnosis and management of depression in the elderly in the long-term care setting. Consult Pharm 1996;11:1241-60.
34. Emptage RE, Semla TP. Depression in the medically ill elderly: a focus on methylphenidate. Ann Pharmacother. 1996;30:151-7. Review.